ScreenerHero

ARGX argenx SE

NAS · US · Healthcare · Biotechnology · argenx.com
928.44USD-0.22%Mkt Cap: 58.08B $P/E: 35.38

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART fo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
BBIO
BridgeBio Pharma, Inc.
$13.00BUSD
CORT
Corcept Therapeutics Incorporated
$12.93BUSDP/E 265.8

Key Statistics

Company
Market Cap58.08B USD
Enterprise Value1.45T USD
Revenue (TTM)5.32B USD
Gross Profit3.70B USD
Net Income (TTM)1.29B USD
Revenue/Share3.44 USD
Last Price928.44 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.9K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)35.38
P/E (Forward)26.80
PEG1.12
EV/EBITDA898.80
EV/Revenue272.73
P/S10.95
P/B172.84
EPS (TTM)26.74
EPS (Forward)34.72
52W Range
661.8565% of range1072.75
52W High1072.75 USD
52W Low661.85 USD
Profitability
Gross Margin89.15%
Oper. Margin31.99%
EBITDA Margin30.34%
Profit Margin31.11%
ROE17.64%
ROA14.88%
Growth
Revenue Growth59.30%
Earnings Growth95.20%
Cash Flow & Leverage
Operating CF685.19M USD
CapEx (TTM)111.68M USD
FCF Margin14.33%
FCF Yield1.31%
Net Debt-5.14B USD
Net Debt/EBITDA-3.18
Balance Sheet
Debt/Equity0.01
Current Ratio5.12
Quick Ratio4.52
Book Value/Sh5.38 USD
Cash/Share3.32 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1180.26 USD
Upside (mean)+27.1%
Target Range900.00 USD – 1450.00 USD
900.00+27.1% to mean1450.00
# Analysts23
Ownership
Shares Out.62.56M
Float1.56B
Insiders0.00%
Institutions46.07%
Short Interest
Short Ratio4.8d
Short % Float2.10%
Short % Out.2.10%
Shares Short1.31M
Short (prev mo.)1.20M
Technical
SMA 50956.61 (-2.9%)
SMA 200851.53 (+9.0%)
Beta-0.04
S&P 52W Chg16.45%
Avg Vol (30d)270.97K
Avg Vol (10d)309.66K
Technical Indicators
RSI (14)41.9
MACD-10.6127
MACD Signal-2.3798
MACD Hist.-8.2329
BB Upper1019.88 USD
BB Middle964.34 USD
BB Lower908.80 USD
BB Width11.52%
ATR (14)25.52 USD
Vol Ratio (20d)0.90x